Biosciences to launch $40M Series A at JPM 2026, advancing CS-0003 mucosal-immune therapies for GI SSI and the GB platform.

The pandemic led to the rapid acceleration in the adoption of telehealth services. In February of this year, there were 38x more outpatient virtual visits compared to February of 2020. Now the ...

Colorado-based cliexa, the maker of various software tools for providers, announced in a blog post yesterday that it has acquired ProSkedge.com, an automated scheduling platform for surgical ...

SAN FRANCISCO, May 5, 2025 /PRNewswire/ -- GI Partners ("GI"), a leading private investment firm, announced today the launch of a tech-enabled Managing General Agency ("MGA") platform in partnership ...

Tim Moran transitions from Chief Executive Officer to Chairman of the Board and Mark Pomeranz appointed Chief Executive Officer to lead next phase of Company Restructuring plan reduces operating ...

SUNRISE, Fla., Nov. 30, 2021 /PRNewswire/ -- ChronWell, a digital health and technology-enabled remote care management company, has announced it has entered into a partnership with the ...

Editor's note: This article has been updated to reflect Health Catalyst Capital not Health Catalyst participated in the round. Digital gastrointestinal health company Vivante Health announced it ...